Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.26

+1.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (10076)	1/21/2004 12:30:23 AM
From: JMarcus	Read Replies (1) of 52153

Rick, I appreciate the perspective of the "been there/been burned" folks re PCYC, but I'm having trouble seeing where the big risk lies in getting Xcytrin approved. All the company appears to need to do is to repeat the result achieved in the last Phase III trial. They've got the SPA for the next trial, so the critical-path-to-success appears to be very well defined and the track record from the last trial gives every confidence that they can get from here to there. If they are remarkable frauds or incompetents, I suppose they could still screw things up, but I just don't see that happening. From the presentation and break-out session, these folks really seemed to be on top of their game. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next